Steven Lieberman at The Sedona Conference Patent Conference (Part 2): Promoting Invention, Entrepreneurship, Economic Growth, and Job Creation

Print PDF Icon
Washington, D.C.

Partner Steven Lieberman will sit on a panel titled "Section 101, Mayo & Myriad and laws of nature" at The Sedona Conference's Patent Conference (Part 2): Promoting Invention, Entrepreneurship, Economic Growth, and Job Creation to be held June 28, 2019, in Washington, D.C.

The June 28 conference will continue the dialogue from the conference held on January 17, 2019, to consider how well the United States patent system is working to foster invention, job creation, industrial competitiveness, wealth creation, and strategic strength in the U.S. The conference will showcase a diverse assembly of thought leaders in patent law engaging in a constructive dialogue, not debate, to explore the present inefficiencies in the U.S. patent system in an effort to develop consensus solutions that will benefit all stakeholders.

A very distinguished group of dialogue leaders will lead all participants in a dialogue on the following topics: patent eligible subject matter, standard essential patents and the New Madison approach to antitrust enforcement, and the availability of preliminary and permanent injunctions.

A description of Steve's panel can be found below.

"Progress in health sciences is affected by the Supreme Court's cases on eligibility, particularly Mayo and Myriad. Investments in biopharma inventions and discoveries, which typically must be enormous, may not be made at all, and therefore prevention, detection and cures not developed as a result of the present uncertainty. Lower courts have failed to provide clarity to the high court's cases, making venture capitalists and other potential investors hesitant. The same is true for corporate executives. Consequently, the potential of major breakthroughs in genetic engineering, personalized medicine and computer-related health invention using artificial intelligence may be precluded. Possible solutions will be discussed as well as comparisons to the wider eligibility available in other nations."

Jump to Page

By using this site, you agree to our updated Privacy Policy and our Terms of Use.